Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Regulation of cell proliferation and apoptosis in neuroblastoma cells by ccp1, a FGF2 downstream gene

Authors: Francesca Pellicano, Rachel E Thomson, Gareth J Inman, Tomoko Iwata

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Coiled-coil domain containing 115 (Ccdc115) or coiled coil protein-1 (ccp1) was previously identified as a downstream gene of Fibroblast Growth Factor 2 (FGF2) highly expressed in embryonic and adult brain. However, its function has not been characterised to date. Here we hypothesized that ccp1 may be a downstream effecter of FGF2, promoting cell proliferation and protecting from apoptosis.

Methods

Forced ccp1 expression in mouse embryonic fibroblast (MEF) and neuroblastoma SK-N-SH cell line, as well as down-regulation of ccp1 expression by siRNA in NIH3T3, was used to characterize the role of ccp1.

Results

Ccp1 over-expression increased cell proliferation, whereas down-regulation of ccp1 expression reduced it. Ccp1 was able to increase cell proliferation in the absence of serum. Furthermore, ccp1 reduced apoptosis upon withdrawal of serum in SK-N-SH. The mitogen-activated protein kinase (MAPK) or ERK Kinase (MEK) inhibitor, U0126, only partially inhibited the ccp1-dependent BrdU incorporation, indicating that other signaling pathway may be involved in ccp1-induced cell proliferation. Induction of Sprouty (SPRY) upon FGF2 treatment was accelerated in ccp1 over-expressing cells.

Conclusions

All together, the results showed that ccp1 regulates cell number by promoting proliferation and suppressing cell death. FGF2 was shown to enhance the effects of ccp1, however, it is likely that other mitogenic factors present in the serum can also enhance the effects. Whether these effects are mediated by FGF2 influencing the ccp1 function or by increasing the ccp1 expression level is still unclear. At least some of the proliferative regulation by ccp1 is mediated by MAPK, however other signaling pathways are likely to be involved.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pellicano F, Inglis-Broadgate SL, Pante G, Ansorge W, Iwata T: Expression of coiled-coil protein 1, a novel gene downstream of FGF2, in the developing brain. Gene Expr Patterns. 2005 Pellicano F, Inglis-Broadgate SL, Pante G, Ansorge W, Iwata T: Expression of coiled-coil protein 1, a novel gene downstream of FGF2, in the developing brain. Gene Expr Patterns. 2005
2.
go back to reference McConnell SK, Kaznowski CE: Cell cycle dependence of laminar determination in developing neocortex. Science. 1991, 254 (5029): 282-285. 10.1126/science.1925583.CrossRefPubMed McConnell SK, Kaznowski CE: Cell cycle dependence of laminar determination in developing neocortex. Science. 1991, 254 (5029): 282-285. 10.1126/science.1925583.CrossRefPubMed
3.
go back to reference Temple S, Qian X: bFGF, neurotrophins, and the control or cortical neurogenesis. Neuron. 1995, 15 (2): 249-252. 10.1016/0896-6273(95)90030-6.CrossRefPubMed Temple S, Qian X: bFGF, neurotrophins, and the control or cortical neurogenesis. Neuron. 1995, 15 (2): 249-252. 10.1016/0896-6273(95)90030-6.CrossRefPubMed
4.
go back to reference Dono R, Texido G, Dussel R, Ehmke H, Zeller R: Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. Embo J. 1998, 17 (15): 4213-4225. 10.1093/emboj/17.15.4213.CrossRefPubMedPubMedCentral Dono R, Texido G, Dussel R, Ehmke H, Zeller R: Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. Embo J. 1998, 17 (15): 4213-4225. 10.1093/emboj/17.15.4213.CrossRefPubMedPubMedCentral
5.
go back to reference Vaccarino FM, Schwartz ML, Raballo R, Nilsen J, Rhee J, Zhou M, Doetschman T, Coffin JD, Wyland JJ, Hung YT: Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci. 1999, 2 (3): 246-253. 10.1038/6350.CrossRefPubMed Vaccarino FM, Schwartz ML, Raballo R, Nilsen J, Rhee J, Zhou M, Doetschman T, Coffin JD, Wyland JJ, Hung YT: Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci. 1999, 2 (3): 246-253. 10.1038/6350.CrossRefPubMed
6.
go back to reference Vaccarino FM, Schwartz ML, Raballo R, Rhee J, Lyn-Cook R: Fibroblast growth factor signaling regulates growth and morphogenesis at multiple steps during brain development. Curr Top Dev Biol. 1999, 46: 179-200. 10.1016/S0070-2153(08)60329-4.CrossRefPubMed Vaccarino FM, Schwartz ML, Raballo R, Rhee J, Lyn-Cook R: Fibroblast growth factor signaling regulates growth and morphogenesis at multiple steps during brain development. Curr Top Dev Biol. 1999, 46: 179-200. 10.1016/S0070-2153(08)60329-4.CrossRefPubMed
7.
go back to reference Davis AA, Temple S: A self-renewing multipotential stem cell in embryonic rat cerebral cortex. Nature. 1994, 372 (6503): 263-266. 10.1038/372263a0.CrossRefPubMed Davis AA, Temple S: A self-renewing multipotential stem cell in embryonic rat cerebral cortex. Nature. 1994, 372 (6503): 263-266. 10.1038/372263a0.CrossRefPubMed
8.
go back to reference Iwata T, Hevner RF: Fibroblast growth factor signaling in development of the cerebral cortex. Dev Growth Differ. 2009, 51 (3): 299-323. 10.1111/j.1440-169X.2009.01104.x.CrossRefPubMed Iwata T, Hevner RF: Fibroblast growth factor signaling in development of the cerebral cortex. Dev Growth Differ. 2009, 51 (3): 299-323. 10.1111/j.1440-169X.2009.01104.x.CrossRefPubMed
9.
go back to reference Hevner RF: The cerebral cortex malformation in thanatophoric dysplasia: neuropathology and pathogenesis. Acta Neuropathol. 2005, 110 (3): 208-221. 10.1007/s00401-005-1059-8.CrossRefPubMed Hevner RF: The cerebral cortex malformation in thanatophoric dysplasia: neuropathology and pathogenesis. Acta Neuropathol. 2005, 110 (3): 208-221. 10.1007/s00401-005-1059-8.CrossRefPubMed
10.
go back to reference Lukaszewicz A, Savatier P, Cortay V, Kennedy H, Dehay C: Contrasting effects of basic fibroblast growth factor and neurotrophin 3 on cell cycle kinetics of mouse cortical stem cells. J Neurosci. 2002, 22 (15): 6610-6622.PubMedPubMedCentral Lukaszewicz A, Savatier P, Cortay V, Kennedy H, Dehay C: Contrasting effects of basic fibroblast growth factor and neurotrophin 3 on cell cycle kinetics of mouse cortical stem cells. J Neurosci. 2002, 22 (15): 6610-6622.PubMedPubMedCentral
11.
go back to reference Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16 (2): 139-149. 10.1016/j.cytogfr.2005.01.001.CrossRefPubMed Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16 (2): 139-149. 10.1016/j.cytogfr.2005.01.001.CrossRefPubMed
12.
go back to reference Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998, 74: 49-139. full_text.CrossRefPubMed Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998, 74: 49-139. full_text.CrossRefPubMed
13.
go back to reference Thisse B, Thisse C: Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol. 2005, 287 (2): 390-402. 10.1016/j.ydbio.2005.09.011.CrossRefPubMed Thisse B, Thisse C: Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol. 2005, 287 (2): 390-402. 10.1016/j.ydbio.2005.09.011.CrossRefPubMed
14.
go back to reference Helgason GV, O'Prey J, Ryan KM: Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res. 70 (10): 4074-4080. 10.1158/0008-5472.CAN-09-2876. Helgason GV, O'Prey J, Ryan KM: Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res. 70 (10): 4074-4080. 10.1158/0008-5472.CAN-09-2876.
15.
go back to reference Kouhara H, Kurebayashi S, Hashimoto K, Kasayama S, Koga M, Kishimoto T, Sato B: Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase. Oncogene. 1995, 10 (12): 2315-2322.PubMed Kouhara H, Kurebayashi S, Hashimoto K, Kasayama S, Koga M, Kishimoto T, Sato B: Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase. Oncogene. 1995, 10 (12): 2315-2322.PubMed
16.
go back to reference Leevers SJ, Paterson HF, Marshall CJ: Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 1994, 369 (6479): 411-414. 10.1038/369411a0.CrossRefPubMed Leevers SJ, Paterson HF, Marshall CJ: Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 1994, 369 (6479): 411-414. 10.1038/369411a0.CrossRefPubMed
17.
go back to reference Kim HJ, Bar-Sagi D: Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol. 2004, 5 (6): 441-450. 10.1038/nrm1400.CrossRefPubMed Kim HJ, Bar-Sagi D: Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol. 2004, 5 (6): 441-450. 10.1038/nrm1400.CrossRefPubMed
18.
go back to reference Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA: sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998, 92 (2): 253-263. 10.1016/S0092-8674(00)80919-8.CrossRefPubMed Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA: sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998, 92 (2): 253-263. 10.1016/S0092-8674(00)80919-8.CrossRefPubMed
19.
go back to reference Turner N, Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10 (2): 116-129. 10.1038/nrc2780. Turner N, Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10 (2): 116-129. 10.1038/nrc2780.
Metadata
Title
Regulation of cell proliferation and apoptosis in neuroblastoma cells by ccp1, a FGF2 downstream gene
Authors
Francesca Pellicano
Rachel E Thomson
Gareth J Inman
Tomoko Iwata
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-657

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine